Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL

View through CrossRef
<div>Abstract<p>Activated B cell–like diffuse large B-cell lymphomas (ABC-DLBCL) have unfavorable outcomes and chronic activation of CARD11–BCL10–MALT1 (CBM) signal amplification complexes that form due to polymerization of BCL10 subunits, which is affected by recurrent somatic mutations in ABC-DLBCLs. Herein, we show that BCL10 mutants fall into at least two functionally distinct classes: missense mutations of the BCL10 CARD domain and truncation of its C-terminal tail. Truncating mutations abrogated a motif through which MALT1 inhibits BCL10 polymerization, trapping MALT1 in its activated filament-bound state. CARD missense mutations enhanced BCL10 filament formation, forming glutamine network structures that stabilize BCL10 filaments. Mutant forms of BCL10 were less dependent on upstream CARD11 activation and thus manifested resistance to BTK inhibitors, whereas BCL10 truncating but not CARD mutants were hypersensitive to MALT1 inhibitors. Therefore, <i>BCL10</i> mutations are potential biomarkers for BTK inhibitor resistance in ABC-DLBCL, and further precision can be achieved by selecting therapy based on specific biochemical effects of distinct mutation classes.</p>Significance:<p>ABC-DLBCLs feature frequent mutations of signaling mediators that converge on the CBM complex. We use structure–function approaches to reveal that <i>BCL10</i> mutations fall into two distinct biochemical classes. Both classes confer resistance to BTK inhibitors, whereas BCL10 truncations confer hyperresponsiveness to MALT1 inhibitors, providing a road map for precision therapies in ABC-DLBCLs.</p><p><i><a href="https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-22-0614" target="_blank">See related commentary by Phelan and Oellerich, p. 1844</a>.</i></p><p><i><a href="https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-12-8-ITI" target="_blank">This article is highlighted in the In This Issue feature, p. 1825</a></i></p></div>
Title: Data from <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Description:
<div>Abstract<p>Activated B cell–like diffuse large B-cell lymphomas (ABC-DLBCL) have unfavorable outcomes and chronic activation of CARD11–BCL10–MALT1 (CBM) signal amplification complexes that form due to polymerization of BCL10 subunits, which is affected by recurrent somatic mutations in ABC-DLBCLs.
Herein, we show that BCL10 mutants fall into at least two functionally distinct classes: missense mutations of the BCL10 CARD domain and truncation of its C-terminal tail.
Truncating mutations abrogated a motif through which MALT1 inhibits BCL10 polymerization, trapping MALT1 in its activated filament-bound state.
CARD missense mutations enhanced BCL10 filament formation, forming glutamine network structures that stabilize BCL10 filaments.
Mutant forms of BCL10 were less dependent on upstream CARD11 activation and thus manifested resistance to BTK inhibitors, whereas BCL10 truncating but not CARD mutants were hypersensitive to MALT1 inhibitors.
Therefore, <i>BCL10</i> mutations are potential biomarkers for BTK inhibitor resistance in ABC-DLBCL, and further precision can be achieved by selecting therapy based on specific biochemical effects of distinct mutation classes.
</p>Significance:<p>ABC-DLBCLs feature frequent mutations of signaling mediators that converge on the CBM complex.
We use structure–function approaches to reveal that <i>BCL10</i> mutations fall into two distinct biochemical classes.
Both classes confer resistance to BTK inhibitors, whereas BCL10 truncations confer hyperresponsiveness to MALT1 inhibitors, providing a road map for precision therapies in ABC-DLBCLs.
</p><p><i><a href="https://aacrjournals.
org/cancerdiscovery/article/doi/10.
1158/2159-8290.
CD-22-0614" target="_blank">See related commentary by Phelan and Oellerich, p.
1844</a>.
</i></p><p><i><a href="https://aacrjournals.
org/cancerdiscovery/article/doi/10.
1158/2159-8290.
CD-12-8-ITI" target="_blank">This article is highlighted in the In This Issue feature, p.
1825</a></i></p></div>.

Related Results

Abstract 3404: Inhibition of BCL10-MALT1 interaction to treat diffuse large B-cell lymphoma
Abstract 3404: Inhibition of BCL10-MALT1 interaction to treat diffuse large B-cell lymphoma
Abstract The CARMA1/BCL10/MALT1 (CBM) signaling complex mediates antigen receptor-induced activation of NF-kB in lymphocytes to support normal adaptive immunity. As ...
Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
Introduction: The activated B-cell-like (ABC) molecular subgroup of diffuse large B-cell lymphoma (DLBCL) is characterized by activation of NF-κB signaling and increased mortality....
Abstract IA06: Molecular classification of diffuse large B-cell lymphoma
Abstract IA06: Molecular classification of diffuse large B-cell lymphoma
Abstract Key PointsSequencing-based approaches are readily used for molecular classifications of diffuse large B-cell lymphomaGenetically distinct diffuse large B-ce...
Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
AbstractBackgroundNon-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB-DLBCL) has worse clinical outcome than GCB-DLBCL, and some relapsed/refractory non-GCB-DLBC...

Back to Top